The global PCOS Diagnostic Market is estimated to be valued at US$ 3.53 Bn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

SWOT Analysis:-

·         Strengths: Ultrasonography as the first line diagnostic method makes diagnosis convenient and accessible. Various diagnostic tests and kits available for comprehensive evaluation.

·         Weaknesses: Reliance on skilled ultrasonographers for accurate diagnosis. Psychological stress and social stigma experienced by PCOS patients.

·         Opportunities: Rising awareness leading to early diagnosis and treatment seeking behavior. Emerging non-invasive diagnostic technologies promising better patient outcomes.

·         Threats: Limited understanding of PCOS etiology poses challenges for disease management. High cost of advanced diagnostic tests restricting market penetration in lower income regions.

Key Takeaways:-

The Global PCOS Diagnostic Market Size was valued at US$ 3.53 Bn in 2023 and is expected to reach over US$ 8 Bn by 2030, expanding at a CAGR of 5% during the forecast period. The growth is attributed to rising prevalence of PCOS worldwide and growing health consciousness among women.

Regional analysis: North America dominated the market in 2023 attributed to the developed healthcare infrastructure and presence of key market players in the region. However, Asia Pacific is anticipated to witness highest growth rate owing to increasing diagnosis rates and heavy government focus on women healthcare in countries like India and China.

Key players: Major market players include Roche Diagnostics, Abbott Laboratories, Quest Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Bio-Rad Laboratories, Agilent Technologies, Hologic, F. Hoffmann-La Roche Ltd., IGENOMIX, Myriad Genetics, Ansh Labs, Diagnostica Stago, Beckman Coulter, and Randox Laboratories Ltd. These players are focusing on launch of advanced diagnostic solutions with high accuracy and minimal invasiveness.

Read More - https://www.feedsfloor.com/other/open-new-avenues-pcos-diagnostic-market